Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug HRS-9813, which is intended for the treatment of idiopathic pulmonary fibrosis (IPF).
Preclinical efficacy data from mouse models of IPF have demonstrated that HRS-9813 significantly improves lung function and reduces pulmonary fibrosis post-administration, exhibiting a favorable safety profile. Notably, there is no similar product that has been approved globally to date. Hengrui has invested RMB 35.39 million in the development of this drug, reflecting the company’s commitment to innovation in addressing unmet medical needs.- Flcube.com
